 |
| (Source: GE Healthcare) |
GE Healthcare has persuaded the Patent Trial and Appeal Board (PTAB) to institute post-grant review (PGR) proceedings against a Johns Hopkins University patent covering imaging and radiotherapeutic agents, while a separate inter partes review (IPR) petition remains pending.
On Jan. 14, 2026, the PTAB agreed to institute a PGR of a Johns Hopkins University patent titled "Imaging and Radiotherapeutics Agents Targeting Fibroblast-Activation Protein-α (FAP-α)" (U.S. Patent No. 12,115,233), following a petition filed by GE Healthcare.
The '233 patent issued in October 2024, and GE Healthcare filed its PGR petition in July 2025. Under U.S. patent law, PGR may be sought only within nine months of a patent's issuance.
Separately, GE Healthcare filed an IPR petition in October 2025 challenging another Johns Hopkins patent titled "Imaging and Radiotherapeutics Agents Targeting Fibroblast-Activation Protein-Alpha (FAP-Alpha)" (U.S. Patent No. 11,938,201). The PTAB has not yet decided whether to institute that IPR.
According to the specification, the '233 patent relates to pharmaceutical compositions for imaging and radiotherapeutic applications that target fibroblast-activation protein-α, a protein overexpressed in cancer-associated fibroblasts and fibrotic diseases.
The challenged patent also has related family members in South Korea, including a granted patent (KR2764076), registered in February 2025, and a pending application (KR1020247035948), both directed to imaging and radiotherapeutic agents targeting FAP-α and held by Johns Hopkins University.
By PatenTrip
Comments
Post a Comment